PDF(Pubmed)
Abstract：
UNASSIGNED: To present the preliminarily findings regarding the effects of a herbal medicine, Ninjin\'yoeito, on comorbid frailty and sarcopenia in patients with chronic obstructive pulmonary disease (COPD).
UNASSIGNED: Patients with COPD (GOLD II or higher) and fatigue were randomly assigned to Group A (n = 28; no medication for 12 weeks, followed by 12-week administration) or B (n= 25; 24-week continuous administration). Visual analog scale (VAS) symptoms of fatigue, the COPD assessment test (CAT), and the modified Medical Research Council (mMRC) Dyspnea Scale were examined. Physical indices such asknee extension leg strength and walking speed, skeletal muscle mass index (SMI), and respiratory function test were also measured.
UNASSIGNED: VAS fatigue scales in Group B significantly improved after 4, 8, and 12 weeks compared to those in Group A (each p<0.001, respectively). Right and left knee extension leg strength in Group B significantly improved after 12 weeks compared to that in Group A (p=0.042 and p=0.037, respectively). The 1-s walking speed for continued to increase significantly over 24 weeks in Group B (p=0.016, p<0.001, p<0.001, p=0.004, p<0.001, and p<0.001 after 4, 8, 12, 16, 20, and 24 weeks, respectively); it also significantly increased after the administration of Ninjin\'yoeito in Group A. In Group B, the SMI significantly increased at 12 weeks in patients with sarcopenia (p=0.025). The CAT scores in Group B significantly improved after 12 weeks compared to those in Group A (p=0.006). The mMRC scores in Group B also significantly improved after 8 and 12 weeks compared to those in Group A (p= 0.045 and p <0.001, respectively). The changes in %FEV1.0 in Group B were significantly improved at 12 and 24 weeks (p=0.039 and p=0.036, respectively).
UNASSIGNED: Overall, Ninjin\'yoeito significantly improved patients\' quality of life, physical activity, muscle mass, and possibly lung function, suggesting that Ninjin\'yoeito may improve frailty and sarcopenia in patients with COPD.
UNASSIGNED: Patients with COPD (GOLD II or higher) and fatigue were randomly assigned to Group A (n = 28; no medication for 12 weeks, followed by 12-week administration) or B (n= 25; 24-week continuous administration). Visual analog scale (VAS) symptoms of fatigue, the COPD assessment test (CAT), and the modified Medical Research Council (mMRC) Dyspnea Scale were examined. Physical indices such asknee extension leg strength and walking speed, skeletal muscle mass index (SMI), and respiratory function test were also measured.
UNASSIGNED: VAS fatigue scales in Group B significantly improved after 4, 8, and 12 weeks compared to those in Group A (each p<0.001, respectively). Right and left knee extension leg strength in Group B significantly improved after 12 weeks compared to that in Group A (p=0.042 and p=0.037, respectively). The 1-s walking speed for continued to increase significantly over 24 weeks in Group B (p=0.016, p<0.001, p<0.001, p=0.004, p<0.001, and p<0.001 after 4, 8, 12, 16, 20, and 24 weeks, respectively); it also significantly increased after the administration of Ninjin\'yoeito in Group A. In Group B, the SMI significantly increased at 12 weeks in patients with sarcopenia (p=0.025). The CAT scores in Group B significantly improved after 12 weeks compared to those in Group A (p=0.006). The mMRC scores in Group B also significantly improved after 8 and 12 weeks compared to those in Group A (p= 0.045 and p <0.001, respectively). The changes in %FEV1.0 in Group B were significantly improved at 12 and 24 weeks (p=0.039 and p=0.036, respectively).
UNASSIGNED: Overall, Ninjin\'yoeito significantly improved patients\' quality of life, physical activity, muscle mass, and possibly lung function, suggesting that Ninjin\'yoeito may improve frailty and sarcopenia in patients with COPD.
摘要：
■要介绍有关草药效果的初步发现，Ninjin\'yoeito,慢性阻塞性肺疾病（COPD）患者的衰弱和肌肉减少症。
■患有慢性阻塞性肺疾病（GOLDII或更高）和疲劳的患者被随机分配到A组（n=28；12周内不用药，然后是12周给药）或B（n=25；24周连续给药）。视觉模拟量表（VAS）疲劳症状，COPD评估测试（CAT），和改良的医学研究理事会（mMRC）呼吸困难量表进行了检查。膝盖伸展腿部力量和步行速度等身体指标，骨骼肌质量指数（SMI），和呼吸功能测试也进行了测量。
■与A组相比，B组的VAS疲劳量表在4、8和12周后显着改善（分别为p<0.001）。与A组相比，B组的右和左膝盖伸展腿力量在12周后显着改善（分别为p=0.042和p=0.037）。B组的1-s步行速度在24周内持续显着增加（在4、8、12、16、20和24周后，p=0.016，p<0.001，p<0.001，p=0.004，p<0.001和p<0.001，分别）；在A组服用Ninjin\'yoeito后，它也显着增加。在B组中，肌肉减少症患者的SMI在12周时显著增加(p=0.025)。与A组相比，B组的CAT评分在12周后显着提高（p=0.006）。与A组相比，B组的mMRC评分在8周和12周后也显着改善（分别为p=0.045和p<0.001）。B组的%FEV1.0的变化在12周和24周时显著改善(分别为p=0.039和p=0.036)。
■总的来说，Ninjin\'yoeito显着改善了患者的生活质量，身体活动,肌肉质量，可能还有肺功能，提示宁津yoeito可以改善COPD患者的虚弱和肌肉减少症。
■患有慢性阻塞性肺疾病（GOLDII或更高）和疲劳的患者被随机分配到A组（n=28；12周内不用药，然后是12周给药）或B（n=25；24周连续给药）。视觉模拟量表（VAS）疲劳症状，COPD评估测试（CAT），和改良的医学研究理事会（mMRC）呼吸困难量表进行了检查。膝盖伸展腿部力量和步行速度等身体指标，骨骼肌质量指数（SMI），和呼吸功能测试也进行了测量。
■与A组相比，B组的VAS疲劳量表在4、8和12周后显着改善（分别为p<0.001）。与A组相比，B组的右和左膝盖伸展腿力量在12周后显着改善（分别为p=0.042和p=0.037）。B组的1-s步行速度在24周内持续显着增加（在4、8、12、16、20和24周后，p=0.016，p<0.001，p<0.001，p=0.004，p<0.001和p<0.001，分别）；在A组服用Ninjin\'yoeito后，它也显着增加。在B组中，肌肉减少症患者的SMI在12周时显著增加(p=0.025)。与A组相比，B组的CAT评分在12周后显着提高（p=0.006）。与A组相比，B组的mMRC评分在8周和12周后也显着改善（分别为p=0.045和p<0.001）。B组的%FEV1.0的变化在12周和24周时显著改善(分别为p=0.039和p=0.036)。
■总的来说，Ninjin\'yoeito显着改善了患者的生活质量，身体活动,肌肉质量，可能还有肺功能，提示宁津yoeito可以改善COPD患者的虚弱和肌肉减少症。
